Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury.

Pharmacogenomics - 1 Jan 2024

Cheng Fang, Qiu Chao-Chao, Jiang Xian-Gao, Wu Te, Zhang Qiang, Chen Xin, Zheng Shi-Lin, Liu Sai-Duo, Ye Xin-Chun, Shi Ji-Chan

Abstract excerpt

The study analyzes the risk factors associated with antituberculosis drug-induced liver injury (ATB-DILI), and the relationship between ATB-DILI and NAT2 gene polymorphisms. Out of the 324 included patients, 57 (17.59%) developed ATB-DILI. Age, history of liver disease, alcohol consumption and timing of antituberculosis (ATB) treatment were independent risk factors for ATB-DILI in the patients with tuberculosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to NAT2 gene

Share to Genotype

Share to Risk Factors

Share to Tuberculosis

Source

Identifiers

PMID: 38131213
DOI: 10.2217/pgs-2023-0148

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury.PMID 38131213Read ↗

Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai PatientsSemantic proximity Read ↗

NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity.Semantic proximity Read ↗

NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Semantic proximity Read ↗

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.Semantic proximity Read ↗

NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients.Semantic proximity Read ↗

Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms.Semantic proximity Read ↗

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.Semantic proximity Read ↗

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.Semantic proximity Read ↗

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.